NCT02045732 - A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL

PF-06342674 0.25 mg/kg

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

Placebo

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

PF-06342674 1.5 mg/kg

Bi-Weekly Subcutaneous Injections X 6

BIOLOGICAL

PF-06342674 6.0 mg/kg

Bi-Weekly Subcutaneous Injections X 6

Trial Locations (8)

Fallon Wellness Pharmacy, Latham

Northeast Eye Center, Latham

The MS Center of Northeastern New York, Latham

Albany Advanced Imaging, Albany

Cleveland Clinic, Cleveland

Retina Vitreous Center, Edmond

Lynn Health Science Institute, Oklahoma City

Radiology Associates (X-ray facility only), Oklahoma City